Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 42 (24) 2853-9
Year:
2024
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-internal-user
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
13
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA189830, UG1CA189954, UG1CA233290, UG1CA233180, UG1CA233337, UG1CA233339; U10CA180863, CCS 707213 (CCTG); U10CA180794, U10CA180820, UG1CA233234 (ECOG-ACRIN); U10CA180868 (NRG Oncology); U10CA180888. UG1CA233163 (SWOG)  
Corr. Author:
 
Authors:
                                             
Networks:
HEARTLAND, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NY016, OH027   
Study
Alliance-A151939
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-80702
Phases:
N/A, 3
Keywords: